GlassScriptPhysician profile
Michelle Lynn Goedken
NPI 1609139138
$50,473.54
in general payments reported to CMS, 2019-2025
23 companies · $489 in 2025
The $489 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $494 · 2021: $16K · 2022: $12K · 2023: $15K · 2024: $6,656 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $1,768 · Travel and Lodging: $107 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,322.50 |
| Food and Beverage | $1,768.05 |
| Travel and Lodging | $106.55 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39,358.73 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $8,635.31 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $411.17 | 2020-2024 | Ilumya |
| Genzyme Corporation | $367.41 | 2020-2025 | |
| Galderma Laboratories, L.P. | $285.40 | 2021-2025 | Nemluvio |
| Leo Pharma INC. | $222.17 | 2020-2025 | Adbry, Anzupgo |
| Pfizer INC. | $200.59 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $164.56 | 2019-2025 | |
| Amgen INC. | $121.15 | 2019-2024 | Otezla |
| Organogenesis INC. | $113.13 | 2023 | Puraply |
| Nalu Medical, INC. | $105.35 | 2023 | Nalu Neurostimulation System |
| Ucb, INC. | $85.64 | 2021-2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $57.82 | 2020-2025 | Libtayo |
| Janssen Biotech, INC. | $54.77 | 2019-2024 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $48.83 | 2020-2021 | |
| Incyte Corporation | $27.97 | 2021 | |
| Dermavant Sciences, INC. | $26.89 | 2024 | Vtama |
| Bioventus LLC | $26.47 | 2022 | |
| Dermira, INC. | $21.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.14 | 2021 | |
| Dusa Pharmaceuticals, INC. | $17.77 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Goedken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.